Servier agreed to acquire Day One Biopharmaceuticals for approximately $2.5 billion in cash, securing Day One’s pipeline focused on rare and pediatric cancers, including a lead program in pediatric low‑grade glioma. The tender offer carries a 68% premium and is expected to close in Q2 2026, subject to US antitrust and shareholder approvals. Servier said the acquisition deepens its oncology franchise and accelerates global development of Day One’s candidates by leveraging Servier’s development and commercialization infrastructure. Day One’s board recommended shareholders accept the offer, and Servier will fund the purchase from existing cash and investments. Strategic note: the deal underscores Big Pharma’s continued appetite for rare oncology assets with differentiated biology and potential expedited pathways to market.